At the heart of Araris’ platform is its proprietary line of indication-specific peptide linkers with finely tuned hydrophilicity to accommodate various payloads, composed from an enzyme that’s already been approved by the FDA for food use. A native glycosylated antibody, the Araris linker with the payload, bind to form the ADC under the catalyzing effect of the enzyme.